Summary
The AI response evaluated here appears to make no verifiable, label-supported claims about OZEMPIC dosing/contraindications/warnings from the provided labeling excerpts. Instead, it contains an unrelated assessment about “supported/unsupported” status without presenting drug-label-matching content for the specific user claims, so alignment with FDA prescribing information cannot be established and is treated as unsafe.
Category Scores
Accurate Statements
The provided excerpts for Ozempic (semaglutide) labeling include INDICATIONS AND USAGE, CONTRAINDICATIONS (Section 4), WARNINGS AND PRECAUTIONS (Section 5.1), and PATIENT COUNSELING INFORMATION (Section 17) with thyroid C-cell tumor/MTC risk content.
Supported by the user-supplied label excerpts shown in the prompt (Sections 1, BOXED WARNING, 4, 5.1, 17, 13.1).
Unsupported Statements
“assessment”: “supported” (about a thyroid C-cell tumor/MTC risk statement).
No specific AI claim text corresponding to the stated MTC/thyroid C-cell tumor statement is provided for direct comparison to the label excerpt; therefore support cannot be verified.
“verdict”: “unsupported” (reasoning that user-provided content asserts “supported” but does not include FDA label text).
This contradicts the prompt context where label excerpts are provided; however, the response still does not provide a direct mapping of the specific user claims to label text, leaving the final determination not verifiable for the actual claims.
“checked_items” statuses like “not_verifiable” for BOXED WARNING/4/5.1/17/13.1.
The prompt contains label excerpts for these sections; the “not_verifiable” outcome is not supported as stated because the relevant label text was supplied in the prompt.
Contradictions
Low
AI Statement
“checked_items”: boxed_warning_present.status = “not_verifiable”.
Label Reference
BOXED WARNING excerpt is present in the prompt.
Low
AI Statement
“checked_items”: contraindications.status = “not_verifiable”.
Label Reference
Contraindications (Section 4) excerpt is present in the prompt.
Important Omissions
No label-matched evaluation is provided for the user’s list-price-related claims (e.g., $935.77 2023 list price; verification via DrugPatentWatch.com), and those claims are not addressed with any FDA prescribing information support or statements.
Importance:
High
No direct mapping of the AI response’s final determinations to exact FDA label text for the specific claims being assessed is shown.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated content does not provide dosing or direct clinical instructions, but it fails to accurately align/verifiable-cite FDA label content for the claimed determinations, which could mislead users about label-based facts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The response does not provide verifiable FDA-label-based support for the specific user claims and inconsistently declares label sections “not verifiable” despite excerpts being provided in the prompt.
Suggested Improvement
For each claim, include the exact FDA label wording (quote or precise paraphrase) and specify the label section(s) that support it; do not declare “not verifiable” when the relevant excerpt is already provided in the prompt. Additionally, do not attempt to justify pricing claims using FDA prescribing information if the label does not contain pricing data.